We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nucleic Acid Test Approved for Sexually Transmitted Parasite

By LabMedica International staff writers
Posted on 11 May 2011
A molecular based assay that detects the protozoan parasite, Trichomonas vaginalis, has received official approval for use in clinical laboratories.

The assay is an in vitro qualitative nucleic acid amplification test (NAAT) that utilizes target capture, chemiluminescent probe hybridization that detect ribosomal ribonucleic acid (rRNA) from T. More...
vaginalis.

The assay is designed to test the following specimens from symptomatic or asymptomatic individuals: clinician-collected endocervical swabs and vaginal swabs, female urine specimens, and specimens collected in specific transport solution. The assay utilizes Target Capture, Transcription-Mediated Amplification (TMA), and Hybridization Protection Assay (HPA) technologies

When the APTIMA Trichomonas vaginalis Assay (Gen-Probe Incorporated, San Diego, CA, USA), is performed, the target rRNA is isolated from the specimen by use of capture oligomers via target capture that utilizes magnetic microparticles. The capture oligomers contain sequences complementary to specific regions of the T. vaginalis rRNA target molecules as well as a string of deoxyadenosine residues. During the hybridization step, the sequence-specific regions of the capture oligomers bind to specific regions of the T. vaginalis rRNA target molecule. The capture oligomer: target complex is then captured out of solution by decreasing the temperature of the reaction to room temperature. The assay is used on the fully automated TIGRIS system, which is also manufactured by Gen-Probe.

Carl W. Hull, MBA, Gen-Probe's president and CEO, said, "Our assay will provide a convenient tool for physicians and laboratories because it employs the same technology as our market-leading tests for Chlamydia and gonorrhea, can be used with the same female samples, and runs on our unique, fully automated TIGRIS system." The APTIMA Trichomonas assay has been cleared for marketing by the US Food and Drug Administration, (FDA, Silver Springs, MD, USA).

T. vaginalis is a sexually transmitted parasite that causes vaginitis, urethritis and cervicitis in women. If left untreated, complications can include premature labor, low-birth-weight offspring, and premature membrane rupture in pregnancy. The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) estimate that 7.4 million American men and women are infected with this parasite annually.

Related Links:
Gen-Probe Incorporated
US Food and Drug Administration
US Centers for Disease Control and Prevention


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.